IBDEI09H ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4373,1,3,0)
 ;;=3^285.8
 ;;^UTILITY(U,$J,358.3,4373,1,4,0)
 ;;=4^ANEMIA NEC
 ;;^UTILITY(U,$J,358.3,4373,2)
 ;;=^87876
 ;;^UTILITY(U,$J,358.3,4374,0)
 ;;=282.2^^37^425^5
 ;;^UTILITY(U,$J,358.3,4374,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4374,1,3,0)
 ;;=3^282.2
 ;;^UTILITY(U,$J,358.3,4374,1,4,0)
 ;;=4^G6Pd DEFICIENCY
 ;;^UTILITY(U,$J,358.3,4374,2)
 ;;=^7225
 ;;^UTILITY(U,$J,358.3,4375,0)
 ;;=V08.^^37^425^6
 ;;^UTILITY(U,$J,358.3,4375,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4375,1,3,0)
 ;;=3^V08.
 ;;^UTILITY(U,$J,358.3,4375,1,4,0)
 ;;=4^HIV+ (ASYMPTOMATIC)
 ;;^UTILITY(U,$J,358.3,4375,2)
 ;;=^303392
 ;;^UTILITY(U,$J,358.3,4376,0)
 ;;=279.3^^37^425^7
 ;;^UTILITY(U,$J,358.3,4376,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4376,1,3,0)
 ;;=3^279.3
 ;;^UTILITY(U,$J,358.3,4376,1,4,0)
 ;;=4^IMMUNITY DEFICIENCY NOS
 ;;^UTILITY(U,$J,358.3,4376,2)
 ;;=^267969
 ;;^UTILITY(U,$J,358.3,4377,0)
 ;;=785.6^^37^425^8
 ;;^UTILITY(U,$J,358.3,4377,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4377,1,3,0)
 ;;=3^785.6
 ;;^UTILITY(U,$J,358.3,4377,1,4,0)
 ;;=4^LYMPHADENOPATHY
 ;;^UTILITY(U,$J,358.3,4377,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,4378,0)
 ;;=075.^^37^425^9
 ;;^UTILITY(U,$J,358.3,4378,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4378,1,3,0)
 ;;=3^075.
 ;;^UTILITY(U,$J,358.3,4378,1,4,0)
 ;;=4^MONONUCLEOSIS
 ;;^UTILITY(U,$J,358.3,4378,2)
 ;;=^62797
 ;;^UTILITY(U,$J,358.3,4379,0)
 ;;=238.4^^37^425^10
 ;;^UTILITY(U,$J,358.3,4379,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4379,1,3,0)
 ;;=3^238.4
 ;;^UTILITY(U,$J,358.3,4379,1,4,0)
 ;;=4^POLYCYTHEMIA VERA
 ;;^UTILITY(U,$J,358.3,4379,2)
 ;;=^304816
 ;;^UTILITY(U,$J,358.3,4380,0)
 ;;=282.49^^37^425^11
 ;;^UTILITY(U,$J,358.3,4380,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4380,1,3,0)
 ;;=3^282.49
 ;;^UTILITY(U,$J,358.3,4380,1,4,0)
 ;;=4^THALASSEMIA NEC
 ;;^UTILITY(U,$J,358.3,4380,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,4381,0)
 ;;=287.5^^37^425^12
 ;;^UTILITY(U,$J,358.3,4381,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4381,1,3,0)
 ;;=3^287.5
 ;;^UTILITY(U,$J,358.3,4381,1,4,0)
 ;;=4^THROMBOCYTOPENIA NOS
 ;;^UTILITY(U,$J,358.3,4381,2)
 ;;=^118988
 ;;^UTILITY(U,$J,358.3,4382,0)
 ;;=289.9^^37^425^13
 ;;^UTILITY(U,$J,358.3,4382,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4382,1,3,0)
 ;;=3^289.9
 ;;^UTILITY(U,$J,358.3,4382,1,4,0)
 ;;=4^THROMBOCYTOSIS
 ;;^UTILITY(U,$J,358.3,4382,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,4383,0)
 ;;=401.9^^37^426^1
 ;;^UTILITY(U,$J,358.3,4383,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4383,1,3,0)
 ;;=3^401.9
 ;;^UTILITY(U,$J,358.3,4383,1,4,0)
 ;;=4^HYPERTENSION NOS
 ;;^UTILITY(U,$J,358.3,4383,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,4384,0)
 ;;=401.1^^37^426^3
 ;;^UTILITY(U,$J,358.3,4384,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4384,1,3,0)
 ;;=3^401.1
 ;;^UTILITY(U,$J,358.3,4384,1,4,0)
 ;;=4^HYPERTENSION,BENIGN
 ;;^UTILITY(U,$J,358.3,4384,2)
 ;;=^269591
 ;;^UTILITY(U,$J,358.3,4385,0)
 ;;=401.0^^37^426^2
 ;;^UTILITY(U,$J,358.3,4385,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4385,1,3,0)
 ;;=3^401.0
 ;;^UTILITY(U,$J,358.3,4385,1,4,0)
 ;;=4^HYPERTENSION,ACCELERATED
 ;;^UTILITY(U,$J,358.3,4385,2)
 ;;=^73505
 ;;^UTILITY(U,$J,358.3,4386,0)
 ;;=227.0^^37^427^1
 ;;^UTILITY(U,$J,358.3,4386,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4386,1,3,0)
 ;;=3^227.0
 ;;^UTILITY(U,$J,358.3,4386,1,4,0)
 ;;=4^ADRENAL NEOPLASM,BENIGN
 ;;^UTILITY(U,$J,358.3,4386,2)
 ;;=^267688
 ;;^UTILITY(U,$J,358.3,4387,0)
 ;;=194.0^^37^427^2
 ;;^UTILITY(U,$J,358.3,4387,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4387,1,3,0)
 ;;=3^194.0
 ;;^UTILITY(U,$J,358.3,4387,1,4,0)
 ;;=4^ADRENAL NEOPLASM,MALIGNANT
